MCAM and cancer: These experiments demonstrated that SEMA3A-overexpressing cancer cells demonstrated reduced breast tumour growth due to the higher activity of PTEN and MelCAM and reduced expression of vascular endothelial growth factor (VEGF) and phosphorylated FOXO3A.